6ehx: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "6ehx" [edit=sysop:move=sysop] |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==scFv AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery== | |||
<StructureSection load='6ehx' size='340' side='right'caption='[[6ehx]], [[Resolution|resolution]] 2.20Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6ehx]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EHX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6EHX FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.2Å</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ehx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ehx OCA], [https://pdbe.org/6ehx PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ehx RCSB], [https://www.ebi.ac.uk/pdbsum/6ehx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ehx ProSAT]</span></td></tr> | |||
</table> | |||
==See Also== | |||
*[[Antibody 3D structures|Antibody 3D structures]] | |||
*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | |||
[[Category: | *[[3D structures of human antibody|3D structures of human antibody]] | ||
[[Category: Hargreaves | __TOC__ | ||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Hargreaves D]] | |||
Latest revision as of 09:52, 23 October 2024
scFv AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery
| ||||||||||||
